Abstract
The development and approval of new antimicrobials capable of being used to treat infections caused by multidrug-resistant pathogens has not kept pace with the rapid emergence of bacterial resistance. Without a doubt, there is a critical unmet need for the identification of novel strategies to develop antimicrobials to deal with this new scourge. One strategy, which warrants special attention as a unique method for identifying new antimicrobials, is drug repurposing. Several approved drugs have been successfully repurposed for different ailments giving hope that this strategy can also be utilized to uncover new antibacterials. To aid in this process, the present review presents non-antimicrobial approved drugs and clinical molecules, which have been shown to possess antimicrobial activity against Staphylococcus aureus and their potential clinical applications. Additionally, approved drugs with novel applications such as interference in staphylococcal pathogenesis and host immunomodulators are also explained. The current review also discusses the challenges associated with repurposing already approved non-antimicrobial drugs as antibacterials and potential uses of these drugs that can be further explored in order to develop novel therapeutics for the treatment of multidrug- resistant staphylococcal infections. Collectively, the information presented demonstrates that repurposing approved drugs and clinical molecules as antimicrobials may help to speed up the drug development process and save years of expensive research invested in antimicrobial drug development.
Keywords: Repurposing, non-antibiotics, multidrug-resistance, staphylococci, MRSA, virulence factors, bacterial resistance, immunomodulatory agents.
Current Pharmaceutical Design
Title:Drug Repurposing for the Treatment of Staphylococcal Infections
Volume: 21 Issue: 16
Author(s): Shankar Thangamani, Haroon Mohammad, Waleed Younis and Mohamed N. Seleem
Affiliation:
Keywords: Repurposing, non-antibiotics, multidrug-resistance, staphylococci, MRSA, virulence factors, bacterial resistance, immunomodulatory agents.
Abstract: The development and approval of new antimicrobials capable of being used to treat infections caused by multidrug-resistant pathogens has not kept pace with the rapid emergence of bacterial resistance. Without a doubt, there is a critical unmet need for the identification of novel strategies to develop antimicrobials to deal with this new scourge. One strategy, which warrants special attention as a unique method for identifying new antimicrobials, is drug repurposing. Several approved drugs have been successfully repurposed for different ailments giving hope that this strategy can also be utilized to uncover new antibacterials. To aid in this process, the present review presents non-antimicrobial approved drugs and clinical molecules, which have been shown to possess antimicrobial activity against Staphylococcus aureus and their potential clinical applications. Additionally, approved drugs with novel applications such as interference in staphylococcal pathogenesis and host immunomodulators are also explained. The current review also discusses the challenges associated with repurposing already approved non-antimicrobial drugs as antibacterials and potential uses of these drugs that can be further explored in order to develop novel therapeutics for the treatment of multidrug- resistant staphylococcal infections. Collectively, the information presented demonstrates that repurposing approved drugs and clinical molecules as antimicrobials may help to speed up the drug development process and save years of expensive research invested in antimicrobial drug development.
Export Options
About this article
Cite this article as:
Thangamani Shankar, Mohammad Haroon, Younis Waleed and Seleem N. Mohamed, Drug Repurposing for the Treatment of Staphylococcal Infections, Current Pharmaceutical Design 2015; 21 (16) . https://dx.doi.org/10.2174/1381612821666150310104416
DOI https://dx.doi.org/10.2174/1381612821666150310104416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects
Current Stem Cell Research & Therapy Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Recent Developments in the Synthesis and Biological Activity of Muramylpeptides
Current Medicinal Chemistry Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity
Mini-Reviews in Medicinal Chemistry Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine
Current HIV Research Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer
Current Cancer Drug Targets Editorial [ Hot Topic: Highlights on Important Signaling Pathways as Drug Targets in Hematological Malignancies (Guest Editors: H. Serve and H.C. Hasselbalch) ]
Current Drug Targets Radiation Protection of the Child from Diagnostic Imaging
Current Pediatric Reviews Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals